Benefit–Risk Profile of Sphingosine-1-Phosphate Receptor Modulators in Relapsing and Secondary Progressive Multiple Sclerosis
Author:
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical)
Link
http://link.springer.com/article/10.1007/s40265-017-0814-1/fulltext.html
Reference73 articles.
1. Gonzalez-Cabrera PJ, Brown S, Studer SM, Rosen H. S1P signaling: new therapies and opportunities. F1000Prime Rep. 2014;6:109. doi: 10.12703/P6-109 .
2. Radick L, Mehr SR. The latest innovations in the drug pipeline for multiple sclerosis. Am Health Drug Benefits. 2015;8(8):448–53.
3. Urbano M, Guerrero M, Rosen H, Roberts E. Modulators of the sphingosine 1-phosphate receptor 1. Bioorg Med Chem Lett. 2013;23(23):6377–89. doi: 10.1016/j.bmcl.2013.09.058 .
4. Aktas O, Kury P, Kieseier B, Hartung HP. Fingolimod is a potential novel therapy for multiple sclerosis. Nat Rev Neurol. 2010;6(7):373–82. doi: 10.1038/nrneurol.2010.76 .
5. Chun J, Hartung HP. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin Neuropharmacol. 2010;33(2):91–101. doi: 10.1097/WNF.0b013e3181cbf825 .
Cited by 55 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Discovery of Potent, Orally Bioavailable Sphingosine-1-Phosphate Transporter (Spns2) Inhibitors;Journal of Medicinal Chemistry;2024-07-02
2. Immune System Dysregulation in the Progression of Multiple Sclerosis: Molecular Insights and Therapeutic Implications;Neuroscience;2024-06
3. The Current Landscape in the Development of Small-molecule Modulators Targeting Sphingosine-1-phosphate Receptors to Treat Neurodegenerative Diseases;Current Topics in Medicinal Chemistry;2024-04-26
4. Pre-existing parasympathetic dominance seems to account for heart rate slowingafter six months of Fingolimod-treatment in patients with multiple sclerosis;2024-03-12
5. Sphingosine 1‐phosphate receptor modulators in multiple sclerosis treatment: A practical review;Annals of Clinical and Translational Neurology;2024-02-16
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3